Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Camrelizumab |
| Indication/Tumor Type | cervical adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | cervical adenocarcinoma | predicted - sensitive | Camrelizumab | Case Reports/Case Series | Actionable | In a clinical case study, Camrelizumab (SHR-1210) treatment resulted in a partial response in the cervical tumor and a complete response in the pulmonary metastases in a patient with CD274 (PD-L1)-positive (IHC = 1%) cervical adenocarcinoma, who previously progressed on chemotherapy treatment (PMID: 35280424). | 35280424 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35280424) | Camrelizumab for the treatment of advanced cervical adenocarcinoma: a case report and literature review. | Full reference... |